TipRanks
Go Ultimate55% OFF

S2Medical AB Class B (S21) AI Stock Analysis

DE:S21

S2Medical AB Class B

(Frankfurt:S21)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Long-term revenue growthThe substantial multi-year revenue increase indicates that S2Medical has expanded its commercial base and product adoption. Although recent growth has weakened, the larger revenue platform provides a foundation for recovery if execution and demand stabilize.
Negative Factors
Volatile revenue trajectoryThe reversal from strong growth to declines reduces confidence in demand durability and forecasting reliability. Continued volatility could weaken operating leverage, make resource planning harder, and delay the ability to convert the expanded revenue base into consistent returns.

S2Medical AB Class B (S21) vs. iShares MSCI Germany ETF (EWG)

Not enough price history over this period.

Market Cap
EUR 628.72K
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.3
Beta (1Y)
13.32
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
10
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

S2Medical AB Class B Business Overview & Revenue Model

Company Description

S2Medical AB (publ) focuses on the development, production, and commercialization of advanced wound care solutions, specifically targeting burns and chronic wounds. Their product range features INSTAQRETT, a sterile, disposable tool for mechanical de...

S2Medical AB Class B Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:S21 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:STILSE:STIL81OutperformSEK 2.23B23.18――28.75%138.25%
SE:ALIF.BSE:ALIF.B74OutperformSEK 22.23B34.6611.32%0.82%1.62%63.45%
SE:ARJO.BSE:ARJO.B69NeutralSEK 9.18B25.354.65%2.82%-0.50%-17.58%
SE:BACTI.BSE:BACTI.B53NeutralSEK 560.70M88.891.93%―-0.51%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:SEDANASE:SEDANA49NeutralSEK 926.81M-26.86-3.88%―0.42%15.03%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%SE:ALIF.BSE:ARJO.BSE:BACTI.BSE:SEDANASE:STILDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:S21 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:S21S2Medical AB Class B―――
SE:ALIF.BAddLife AB Class B182.30-14.65-7.44%
SE:ARJO.BArjo AB Class B33.723.9413.22%
SE:BACTI.BBactiguard Holding AB16.00-0.20-1.23%
SE:SEDANASedana Medical AB9.33-0.75-7.44%
SE:STILStille AB248.5072.0040.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.